Vojo Vukovic

1.1k total citations
13 papers, 440 citations indexed

About

Vojo Vukovic is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Vojo Vukovic has authored 13 papers receiving a total of 440 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Molecular Biology, 5 papers in Oncology and 3 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Vojo Vukovic's work include Heat shock proteins research (6 papers), Cancer Treatment and Pharmacology (4 papers) and Cancer Genomics and Diagnostics (3 papers). Vojo Vukovic is often cited by papers focused on Heat shock proteins research (6 papers), Cancer Treatment and Pharmacology (4 papers) and Cancer Genomics and Diagnostics (3 papers). Vojo Vukovic collaborates with scholars based in United States, United Kingdom and Poland. Vojo Vukovic's co-authors include Wei Guo, Axel Hauschild, Steven O’Day, Joelle Lufkin, Caroline Robert, Laurent Mortier, Alessandro Testori, Safi R. Bahcall, Philip Friedlander and Richard Kefford and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Vojo Vukovic

13 papers receiving 436 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Vojo Vukovic United States 7 277 125 99 81 71 13 440
Ziyan Y. Pessetto United States 12 284 1.0× 132 1.1× 67 0.7× 113 1.4× 73 1.0× 22 521
Amy J. Aldrich United States 8 294 1.1× 150 1.2× 42 0.4× 85 1.0× 34 0.5× 8 503
Dinesh Chimmanamada United States 6 170 0.6× 98 0.8× 61 0.6× 57 0.7× 103 1.5× 7 383
Rongzhen Lu United States 6 540 1.9× 140 1.1× 65 0.7× 187 2.3× 110 1.5× 6 808
Manel Jendoubi France 9 256 0.9× 81 0.6× 41 0.4× 117 1.4× 24 0.3× 14 453
Maria Rita Milone Italy 12 321 1.2× 134 1.1× 119 1.2× 182 2.2× 26 0.4× 16 556
A. Andrea Gudiel United States 6 285 1.0× 159 1.3× 129 1.3× 138 1.7× 143 2.0× 6 532
Agnès Basseville United States 11 321 1.2× 239 1.9× 32 0.3× 56 0.7× 32 0.5× 18 521
Paola Corazao-Rozas France 5 302 1.1× 101 0.8× 29 0.3× 125 1.5× 23 0.3× 5 405
Ling Xie United States 14 496 1.8× 138 1.1× 25 0.3× 63 0.8× 61 0.9× 31 641

Countries citing papers authored by Vojo Vukovic

Since Specialization
Citations

This map shows the geographic impact of Vojo Vukovic's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Vojo Vukovic with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Vojo Vukovic more than expected).

Fields of papers citing papers by Vojo Vukovic

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Vojo Vukovic. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Vojo Vukovic. The network helps show where Vojo Vukovic may publish in the future.

Co-authorship network of co-authors of Vojo Vukovic

This figure shows the co-authorship network connecting the top 25 collaborators of Vojo Vukovic. A scholar is included among the top collaborators of Vojo Vukovic based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Vojo Vukovic. Vojo Vukovic is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

13 of 13 papers shown
1.
Pillai, Rathi N., Dean A. Fennell, Vladimir Kovčin, et al.. (2019). Randomized Phase III Study of Ganetespib, a Heat Shock Protein 90 Inhibitor, With Docetaxel Versus Docetaxel in Advanced Non–Small-Cell Lung Cancer (GALAXY-2). Journal of Clinical Oncology. 38(6). 613–622. 53 indexed citations
2.
Pillai, Rathi N., Dean A. Fennell, Vladimir Kovčin, et al.. (2017). PL03.09: Phase 3 Study of Ganetespib, a Heat Shock Protein 90 Inhibitor, with Docetaxel versus Docetaxel in Advanced Non-Small Cell Lung Cancer (GALAXY-2). Journal of Thoracic Oncology. 12(1). S7–S8. 12 indexed citations
3.
O’Day, Steven, Alexander M.M. Eggermont, Vanna Chiarion‐Sileni, et al.. (2013). Final Results of Phase III SYMMETRY Study: Randomized, Double-Blind Trial of Elesclomol Plus Paclitaxel Versus Paclitaxel Alone As Treatment for Chemotherapy-Naive Patients With Advanced Melanoma. Journal of Clinical Oncology. 31(9). 1211–1218. 236 indexed citations
4.
5.
6.
7.
8.
9.
Jhaveri, Komal, Sarat Chandarlapaty, Diana Lake, et al.. (2011). P1-17-08: A Phase II Trial of Ganetespib: Efficacy and Safety in Patients (pts) with Metastatic Breast Cancer (MBC).. Cancer Research. 71(24_Supplement). P1–17. 7 indexed citations
10.
Heath, Elisabeth I., Bruce J. Dezube, Leena Gandhi, et al.. (2010). A phase I dose-escalation study of the Hsp90 inhibitor STA-9090 administered twice weekly in patients with solid tumors.. Journal of Clinical Oncology. 28(15_suppl). 3083–3083. 14 indexed citations
11.
Vukovic, Vojo, et al.. (2010). A phase I dose-escalation study of the Hsp90 inhibitor STA-9090 administered once weekly in patients with solid tumors.. Journal of Clinical Oncology. 28(15_suppl). 2529–2529. 14 indexed citations
12.
Vukovic, Vojo, Axel Hauschild, A.M.M. Eggermont, & Steven O’Day. (2010). Phase III, randomized, double-blind study of elesclomol and paclitaxel versus paclitaxel alone in stage IV metastatic melanoma (MM): 1-year OS update.. Journal of Clinical Oncology. 28(15_suppl). 8550–8550. 4 indexed citations
13.
Hillmen, Peter, Aleksander B. Skotnicki, Tadeusz Robak, et al.. (2004). Preliminary Safety and Efficacy Report of a Randomized Trial of Alemtuzumab vs Chlorambucil as Front-Line Therapy in 297 Patients with Progressive B-Cell Chronic Lymphocytic Leukemia.. Blood. 104(11). 2505–2505. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ziyan Y. Pessetto Breakdown of academic impact, for papers by Amy J. Aldrich Breakdown of academic impact, for papers by Dinesh Chimmanamada Breakdown of academic impact, for papers by Rongzhen Lu Breakdown of academic impact, for papers by Manel Jendoubi Breakdown of academic impact, for papers by Maria Rita Milone Breakdown of academic impact, for papers by A. Andrea Gudiel Breakdown of academic impact, for papers by Agnès Basseville Breakdown of academic impact, for papers by Paola Corazao-Rozas Breakdown of academic impact, for papers by Ling Xie
Rankless by CCL
2026